Merrimack Pharmaceuticals, Inc
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts. Show More...
-
Website http://www.merrimack.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 14.73 USD
-
Last Updated 25-04-2024
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -44.17 -9.42 -12.8 -13.2 -8.0 -13.29 -12.11 35.67 -3.03 -1.3 -0.5 Dividends USD Payout Ratio % * Shares Mil 1.0 9.0 7.0 10.0 10.0 11.0 13.0 13.0 13.0 13.0 13.0 Book Value Per Share * USD -0.68 -1.59 -9.35 -12.18 -17.42 8.37 5.02 1.5 1.35 Free Cash Flow Per Share * USD -11.4 -10.1 -3.48 -13.14 -12.33 -11.64 -6.89 -3.57 Return on Assets % -71.71 -110.9 -77.92 -76.7 -47.45 -75.19 -95.93 474.86 -39.35 -31.91 -13.85 Financial Leverage (Average) 1.22 1.51 1.16 1.18 Return on Equity % -52.23 -45.53 -19.77 Return on Invested Capital % -44.16 -43.69 -18.0 Interest Coverage -12.46 -164.92 -10.95 -3.58 -6.68 -2.52 -2.42 -70.61 -13.88 -10.46 Current Ratio 2.22 2.51 3.33 2.89 1.19 1.94 0.65 4.81 5.14 6.75 6.06 Quick Ratio 2.11 2.21 3.1 2.79 1.15 1.85 0.44 4.73 4.82 5.99 5.47 Debt/Equity 0.25